A deadly legacy

Here's today's Big Take.

View in browser

Dec. 23, 2022

Cassandra said most people in her family with ALS have died in 12 to 18 months. Photographer: Ryan Collerd/Bloomberg

Read the story For generations, members of the Weber family have died of ALS. A drug developed by Biogen that targets the gene responsible could help, though clinical-trial data offer conflicting signals. That is likely to leave regulators with a thorny problem: Should they approve a therapy that may not work?  Read The Big Take.

Listen to the podcast Bloomberg chief medical writer Robert Langreth joins this episode to talk about the race to find a treatment for ALS – and the back and forth between patients, companies and government regulators as the struggle to get drugs for life-threatening conditions to market quickly grows more acute. Subscribe and listen on iHeart, Apple and Spotify.

Follow Us

Like getting this newsletter? Subscribe to Bloomberg.com for unlimited access to trusted, data-driven journalism and subscriber-only insights. You received this message because you are subscribed to Bloomberg's The Big Take newsletter. If a friend forwarded you this message, sign up here to get it in your inbox. Unsubscribe Bloomberg.com Contact Us Bloomberg L.P. 731 Lexington Avenue, New York, NY 10022